Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of Ocrelizumab for Patients with Progressive Multiple Sclerosis

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Featured sites

Sites that work closely with us on this trial

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effectiveness and safety of a treatment for Progressive Multiple Sclerosis (PMS), a type of multiple sclerosis where symptoms gradually worsen over time. The treatment being tested is called Ocrelizumab, which is administered as a solution for infusion. The study aims to understand how well this treatment works in managing the disease and ensuring patient safety.

Participants in the study will receive Ocrelizumab over a period of four years. During this time, researchers will monitor the patients to see if there is any progression of the disease and to check for any side effects. The study will also involve regular assessments to evaluate changes in cognitive function, mobility, and overall impact on daily life. These assessments will help determine the effectiveness of the treatment in slowing down or stopping the progression of the disease.

In addition to Ocrelizumab, other medications such as Diphenhydramine Hydrochloride, Paracetamol, and Methylprednisolone may be used as part of the study to manage symptoms or side effects. The study will also include a placebo group to compare the results. The goal is to gather comprehensive data on how Ocrelizumab affects patients with Progressive Multiple Sclerosis and to ensure that the treatment is both effective and safe for long-term use.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of progressive multiple sclerosis (PMS) and ensuring the Expanded Disability Status Scale (EDSS) score is 6.5 or less.

    The assessment also checks for documented evidence of disability progression over the past two years, independent of any relapses.

  2. Step 2

    Baseline evaluation

    A baseline evaluation is performed to measure cognitive function and other health parameters. Tests such as the Symbol Digit Modalities Test (SDMT) and the Brief Visuospatial Memory Test – Revised (BVMT-R) are used.

    Patient-reported outcomes are collected using various scales, including the Multiple Sclerosis Impact Scale and the Fatigue Scale for Motor and Cognitive function.

  3. Step 3

    Medication administration

    The primary medication, ocrelizumab, is administered as an intravenous (IV) infusion. The dosage is 300 mg, and the infusion is repeated at specified intervals throughout the study.

    Additional medications include diphenhydramine hydrochloride (50 mg tablet) and paracetamol (1000 mg oral solution) to manage potential infusion-related reactions.

    A methylprednisolone infusion (500 mg) is also administered to reduce the risk of infusion reactions.

  4. Step 4

    Ongoing assessments

    Regular assessments are conducted to monitor the effectiveness and safety of the treatment. This includes tracking changes in cognitive function, disability status, and other health indicators.

    MRI scans are performed to evaluate changes in brain volume and lesion characteristics.

  5. Step 5

    Final evaluation

    At the end of the study period, a final evaluation is conducted to assess the overall impact of the treatment on disease progression and patient well-being.

    The study aims to determine the proportion of patients with no evidence of progression and no active disease sustained for at least 24 weeks.

Who can join the trial?

6 criteria

  • Must have a confirmed diagnosis of Progressive Multiple Sclerosis (PMS). This is a type of multiple sclerosis where symptoms gradually get worse over time.
  • Must have an EDSS score of 6.5 or less at the screening. The Expanded Disability Status Scale (EDSS) is a method to measure disability in people with multiple sclerosis.
  • Must show evidence of disability getting worse over the last 2 years, not related to relapses. A relapse is a sudden worsening of symptoms.
  • Must meet at least one of the 21 criteria that show disability progression without relapses in the last 2 years, according to a specific checklist used before the study starts.
  • Must have experience using a smartphone and connecting it to Wi-Fi.
  • For women who can have children: Must agree to not get pregnant by either not having sex or using birth control during the study and for at least 6 months after the last dose of the study drug.

Who cannot join the trial?

5 criteria

  • Patients who do not have **Progressive Multiple Sclerosis (PMS)** cannot participate. This is a type of multiple sclerosis where symptoms gradually get worse over time.
  • Patients who are not within the specified age range for the study cannot participate. The age range is not specified here, but it is important for eligibility.
  • Patients who are not part of the specified clinical trial group cannot participate. This refers to a specific group of patients that the study is focusing on.
  • Patients who are not either male or female cannot participate. The study includes both male and female participants.
  • Patients who are not considered part of a vulnerable population cannot participate. Vulnerable populations may include groups like children, pregnant women, or those with certain health conditions.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Ocrelizumab is a medication used in this clinical trial to treat patients with progressive multiple sclerosis (PMS). It works by targeting specific cells in the immune system that are believed to contribute to the progression of multiple sclerosis. The goal of using ocrelizumab in this study is to assess its effectiveness and safety over a four-year period in managing the symptoms and progression of PMS.

What is already known about the treatment

Ocrelizumab – Ocrelizumab is administered as an intravenous infusion, typically given in a healthcare setting. It is currently approved and recognized in medical literature for its use in treating multiple sclerosis, specifically progressive forms of the disease. The main therapeutic indication for ocrelizumab is progressive multiple sclerosis (PMS). At the molecular level, ocrelizumab works by targeting and depleting CD20-positive B cells, which are believed to play a role in the abnormal immune response that damages the nervous system in multiple sclerosis. It is classified pharmacologically as a monoclonal antibody.

Investigated diseases

Progressive Multiple Sclerosis – Progressive multiple sclerosis is a form of multiple sclerosis characterized by a gradual worsening of neurological function over time. Unlike relapsing forms, it does not have distinct relapses or remissions. Symptoms may include increasing difficulty with walking, balance, and coordination, as well as cognitive changes. The disease can affect various parts of the nervous system, leading to a wide range of symptoms. Over time, individuals may experience a steady decline in physical and cognitive abilities. The progression rate can vary significantly from person to person.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-506429-13-00Protocol codeMN39159Estimated enrolment880 patientsSponsorF. Hoffmann-La Roche AG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.